Phathom Pharmaceuticals (PHAT) Interest Coverage Ratio (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Interest Coverage Ratio of 0.16 for Q2 2026, up 93.45% year-over-year from 0.08 in Q2 2025, and up 65.67% quarter-over-quarter from 0.45 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Interest Coverage Ratio (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Interest Coverage Ratio for 9 consecutive years, with 0.16 the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest Coverage Ratio rose 93.45% year-over-year to 0.16; the TTM figure through Jun 2026 stood at 1.59 (up 85.05% YoY), while the FY2025 annual figure was 0.52, up 51.83% from the prior year.
- Interest Coverage Ratio improved to 0.16 in Q2 2026 per PHAT's latest filing, from 0.45 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 1.64 in Q4 2024 and bottomed at 22.26 in Q4 2022.
- Historically, Interest Coverage Ratio has averaged 4.22 across 5 years, with a median of 2.82 in 2023.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio sank 684.34% — and 2024, when it jumped 169.13%.
- Phathom Pharmaceuticals' Interest Coverage Ratio stood at 22.26 in 2022, then soared by 89.31% to 2.38 in 2023, then jumped by 169.13% to 1.64 in 2024, then slumped by 121.95% to 0.36 in 2025, then soared by 57.0% to 0.16 in 2026.
- Business Quant data shows PHAT's Interest Coverage Ratio at 0.16 in Q2 2026, 0.45 in Q1 2026, and 0.36 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | -0.26 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.26 |
| Mar 31, 2026 | -0.98 |
| Dec 31, 2025 | -0.36 |
| Sep 30, 2025 | -0.95 |
| Jun 30, 2025 | -3.42 |
| Mar 31, 2025 | -4.36 |
| Dec 31, 2024 | -3.20 |
| Sep 30, 2024 | -3.83 |
| Jun 30, 2024 | -4.35 |
| Mar 31, 2024 | -4.07 |
| Dec 31, 2023 | -5.36 |
| Sep 30, 2023 | -3.53 |
| Jun 30, 2023 | -3.30 |
| Mar 31, 2023 | -3.26 |
| Dec 31, 2022 | -4.86 |
| Sep 30, 2022 | -4.58 |
| Jun 30, 2022 | -8.00 |
| Mar 31, 2022 | -13.74 |
| Dec 31, 2021 | -11.91 |
| Sep 30, 2021 | -22.31 |